However, in combination trials, there has been evidence of a possible antagonism between delphinidin and HER2-directed therapy, raising concerns regarding potential pharmacological antagonism when used with other targeted therapies in HER2-overexpressing breast cancer [5]. This evidence concerns the gene ERBB2 and breast carcinoma.